Patient eligibility

This study collected the data from CRLM patients who received NC and underwent hepatic resection between September 2003 and August 2020 at the Hepatopancreatobiliary Surgery Department of Peking University Cancer Hospital. The demographic and clinical data were retrospectively obtained from a prospective patient database. The inclusion criteria were: (1) Evaluated to be resectable by a multidisciplinary team (MDT) that consisted of surgical oncologists, radiologists, and medical oncologists; (2) Received NC and underwent hepatic resection; (3) No other simultaneous malignancies; (4) 19-80 years of age; and (5) Eastern Cooperative Oncology Group performance status < 2. Patients who underwent only ablation or palliative hepatic resection (R2) were excluded. This study was approved by the Ethics Committee of Beijing Cancer Hospital (No. 2021YJZ06-GZ01), and the requirement for informed consent was waived.